Navigation Links
Senesco Technologies, Inc. Announces the Appointment of Dr. Harlan W. Waksal, M.D. as Chairman of the Board of Directors and the Addition of Mr. Warren J. Isabelle, CFA to its Board of Directors
Date:6/9/2009

NEW BRUNSWICK, N.J., June 9 /PRNewswire-FirstCall/ -- Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Amex: SNT) today announced the appointment, effective June 8, 2009, of its current Board member, Dr. Harlan Waksal, M.D., to serve as Chairman of the Board, succeeding Mr. Rudolf Stalder, who has been the Company's Chairman since January 2000. Mr. Stalder will continue serving on the Board and also serve as a member of a newly formed Executive Committee that includes Dr. Harlan Waksal, Mr. Christopher Forbes and Mr. Rudolf Stalder.

Dr. Waksal joined the Board of Senesco in October 2008. Dr. Waksal is President and sole Proprietor of Waksal Consulting L.L.C. in Montclair, NJ. From 1984 through July 2003, he was with ImClone Systems Inc., New York, NY, serving most recently as President, Chief Executive Officer and Chief Operating Officer.

Dr. Waksal is a member of the Board of Trustees of Oberlin College Ohio, a member of the Board of Trustees and chair of the New Jersey Region of the American Committee for the Weizmann Institute of Science in New York, and a member of the Board of Trustees of the Montclair Art Museum.

The Board is also pleased to announce, effective June 8, 2009, the appointment of Mr. Warren J. Isabelle, CFA to the Board. Mr. Isabelle is a founder and principal of Ironwood Investment Management L.L.C., located in Boston, MA. From 1983-1997, Mr. Isabelle was with Pioneer Management Corporation where he served most recently as Director of Research and Head of U.S. Equities. Mr. Isabelle also serves as a member of the Public Board and the Investment Committee of the University of Massachusetts Foundation.

Mr. Stalder commented, "With Senesco's groundbreaking technologies, its research focus on human health and its plans to move diligently into clinical trials with a Multiple Myeloma cancer project, the recent addition of Dr. Waksal to Senesco's Board gave us a unique opportunity to ask him to take on these new responsibilities as Chairman of the Board. His experience in this area will best serve our efforts moving forward. We are very pleased about his acceptance of this significant role."

Dr. Waksal commented about his new responsibilities, "I am excited to take on this new role in a company that is applying cutting edge science to areas of unmet medical need. The evolving and significant scientific work and the near term possibility of entering human studies make this a particularly promising time for Senesco. I look forward to helping bring this work to fruition through my interaction with management in my new role."

About Senesco Technologies, Inc.

Senesco Technologies, Inc. is a U.S. biotechnology company, headquartered in New Brunswick, NJ. Senesco has initiated preclinical research to trigger or delay cell death in mammals (apoptosis) to determine if the technology is applicable in human medicine. Accelerating apoptosis may have applications to development of cancer treatments. Delaying apoptosis may have applications to certain inflammatory and ischemic diseases. Senesco takes its name from the scientific term for the aging of plant cells: senescence. Delaying cell breakdown in plants extends freshness after harvesting, while increasing crop yields, plant size and resistance to environmental stress. The Company believes that its technology can be used to develop superior strains of crops without any modification other than delaying natural plant senescence. Senesco has partnered with leading-edge companies engaged in agricultural biotechnology and earns research and development fees for applying its gene-regulating platform technology to enhance its partners' products.

Certain statements included in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors, including, but not limited to: the ability of the Company to consummate a financing; the development of the Company's gene technology; the approval of the Company's patent applications; the successful implementation of the Company's research and development programs and joint ventures; the success of the Company's license agreements; the acceptance by the market of the Company's products; success of the Company's preliminary studies and preclinical research; competition and the timing of projects and trends in future operating performance, the Company's ability to meet its funding milestones under its financing transaction, the Company's ability to continue to comply with the continued listing standards of the AMEX, as well as other factors expressed from time to time in the Company's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with the Company's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

    Company Contact:
    Senesco Technologies, Inc.
    Bruce Galton
    Chief Executive Officer
    bgalton@senesco.com
    (732) 296-8400

    Investor Relations Contact:
    FD
    Brian Ritchie
    brian.ritchie@fd.com
    212-850-5600

    Media Relations Contact:
    FD
    Irma Gomez-Dib
    irma.gomez-dib@fd.com
    212-850-5600


'/>"/>
SOURCE Senesco Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Senesco Presents Pre-Clinical Multiple Myeloma Data at the 12th Annual Meeting of the American Society of Gene Therapy
2. Senesco Technologies Reports Third Quarter Fiscal 2009 Financial Results
3. Senesco Technologies Reports Second Quarter Fiscal 2009 Financial Results
4. Senesco and Harris Moran Mutually Agree to Terminate Development and License Agreement Due to Restructuring
5. Senesco Appoints Harlan W. Waksal, M.D., to Board of Directors
6. Senescos Preclinical Multiple Myeloma Data to be Presented at the 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
7. Senesco Technologies Announces Successful Completion of First Milestone Related to Agreement with Bayer CropScience
8. Senesco Technologies Closes Remaining $3.0 Million of Previously Announced Financing
9. Senesco Signs a Supply Agreement for Polyplus-transfections Delivery System
10. Senesco Technologies to Present at BIO 2008 Business Forum
11. Senesco Technologies Reports Third Quarter Fiscal 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... LOUISVILLE, Ky. , June 23, 2016 /PRNewswire/ ... from two Phase 1 clinical trials of its ... double-blind, placebo-controlled, single and multiple ascending dose studies ... and pharmacodynamics (PD) of subcutaneous injection in healthy ... APL-2 subcutaneously (SC) either as a single dose ...
(Date:6/23/2016)... NEW YORK , June 23, 2016 ... the trading session at 4,833.32, down 0.22%; the Dow Jones ... the S&P 500 closed at 2,085.45, down 0.17%. Stock-Callers.com has ... INFI ), Nektar Therapeutics (NASDAQ: NKTR ... BIND Therapeutics Inc. (NASDAQ: BIND ). Learn more ...
(Date:6/23/2016)... ... June 23, 2016 , ... Velocity Products, ... tools designed, tuned and optimized exclusively for Okuma CNC machining centers at The ... of a collaboration among several companies with expertise in toolholding, cutting tools, machining ...
(Date:6/22/2016)... , June 22, 2016 Cell Applications, ... allow them to produce up to one billion ... lot within one week. These high-quality, consistent stem ... preparing cells and spend more time doing meaningful, ... a proprietary, high-volume manufacturing process that produces affordable, ...
Breaking Biology Technology:
(Date:6/2/2016)... NEW YORK , June 2, 2016   The ... (Weather), is announcing Watson Ads, an industry-first capability in which ... advertising, by being able to ask questions via voice or ... Marketers have long ... with the consumer, that can be personal, relevant and valuable; ...
(Date:5/24/2016)... IRVINE, Calif. , May 24, 2016 Ampronix facilitates superior patient care ... LMD3251MT  3D medical LCD display is the latest premium product recently added to ... ... ... Sony 3d Imaging- LCD Medical Display- Ampronix News ...
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com , ... published the overview results from the Q1 wave of ... recent wave was consumers, receptivity to a program where ... with a health insurance company. "We were ... share," says Michael LaColla , CEO of Troubadour ...
Breaking Biology News(10 mins):